Crucial Fact

  • Her favourite word was fact.

Last in Parliament November 2005, as Liberal MP for Edmonton Centre (Alberta)

Lost her last election, in 2006, with 39% of the vote.

Statements in the House

Question No. 148 June 4th, 2002

Drugs are delisted from the non-insured health benefits, NIHB, drug benefit list when:

(a) the drug has been discontinued from the Canadian market; new products possessing clearly demonstrated therapeutic and safety advantages or improvements have been listed; new toxicity data shift the risk-benefit ratio to make the continued listing of the product inappropriate; new information demonstrates that the product does not have the anticipated therapeutic benefit; the purchase cost is disproportionate to the benefits provided; and, the drug has a high potential for misuse or abuse.

(b) The NIHB program was established to assist in addressing the poor health status of first nations and Inuit people. Where the provinces/territories have not specifically excluded first nations and Inuit from drug plans and programs, AIDS, Methadone, the program does co-ordinate the funding.

(c) The provision of drug benefits to first nations and Inuit groups, as stated in the 1979 Indian health policy, is a shared responsibility between the federal, provincial, territorial governments and first nations and Inuit. The provinces and territories, through their drug plans, ensure access for provincial residents. The NIHB program meets that responsibility for first nations and Inuit people. We work closely with the provincial and territorial drugs plans in the listing of benefits, and through activities such as the common drug review announced by the premiers in January 2002. In doing so the premiers directed their health ministers to develop common recommendations for the approval of all new drugs to be covered under federal, provincial and territorial plans by the end of August 2002.

Health May 30th, 2002

Mr. Speaker, the hon. member is correct that the total cost of drugs in the health care system does continue to rise. This is a matter that was identified as being of concern for first ministers and was addressed in the accord signed in September 2000 by the Prime Minister and the premiers.

The federal government and provincial and territorial health ministers continue to work together, dare I say very effectively, in relation to dealing with tough issues around drug utilization, prices of individual drugs and the total cost of drugs to the health care system.

Question No. 156 May 29th, 2002

(a) In cases where the shelf life of a food product is expected to be more than 90 days, there is no general requirement to label such products with a “best before” or “packaged on” date. Of course, all other labelling requirements, e.g. ingredient listing, common name, et cetera, apply unless exceptions are noted.

(b) As noted above, there is no general requirement to label products with a shelf life expected to be more than 90 days with a “best before” or “packaged on” date.

However, there are two types of products that may have a shelf life of over 90 days for which a requirement for date of packaging or date of processing on the label applies. These are “low-acid foods packaged in hermetically sealed containers” and “whole cheese that is not made from a pasteurized source”.

The regulations pertaining to a requirement for the indication of a date on the label for these types of products are quoted below:

B.27.005 states that “No person shall sell a commercially sterile low-acid food packaged in a hermetically sealed container unless (a) the label or container of the food bears a code or lot number that identifies, in a legible and permanent manner, (i) the establishment in which the product was rendered commercially sterile, and (ii) the day, month and year on which the food was rendered commercially sterile; and (b) the exact meaning of each item in any code or lot number referred to in paragraph (a) is available to an inspector at the establishment or, where the food is imported, from the importer”.

B.08.042 states that “No manufacturer shall sell whole cheese that is not made from a pasteurized source unless the date of the beginning of the manufacturing process is (a) marked or branded thereon within three days thereof or (b) marked on the label at the time of packaging, if the cheese is such that, because of its texture, consistency, or physical structure, such date cannot be effectively branded or marked on the cheese”.

In addition, there are certain foods for which expiration dates are required. Note that these foods all have specific nutritional requirements and several of them are used as sole sources of nutrition.

These are: Formulated liquid diets: B.24.103(g); Meal replacements and nutritional supplements: B.24.202(d); Foods represented for use in a low energy diet: B.24.304(h); Infant formulas, or human milk substitutes, and foods containing human milk substitutes: B.25.057(1)(f) and (2)(f)

“Expiration date”, B.24.001 and B.25.001, for these products means “the date (a) after which the manufacturer does not recommend that it be consumed, and (b) up to which it maintains its microbiological and physical stability and the nutrient content declared on the label”.

(c) There is no current activity with respect to putting forward such regulations.

(d) A durable life date provides consumers with an indication of the date until which a food, stored under appropriate conditions, would “retain its normal wholesomeness, palatability, nutritional value and any other qualities claimed for it by the manufacturer”. A growing number of Canadian companies have voluntarily adopted “best before” dating for their foods with a shelf life greater than 90 days to provide more information to their customers. This trend is expected to continue.

Regardless of whether a food is within or beyond its stated durable life date, if a food is considered to pose a hazard, it must be dealt with by the Canadian Food Inspection Agency, CFIA, or other relevant authority. In the course of an investigation, the CFIA may make a request to Health Canada for a health risk assessment, HRA. It is, nevertheless, the responsibility of food manufacturers/importers to ensure the safety of the food they put on the market and to ensure that the durable life date is valid.

Health May 28th, 2002

Mr. Speaker, indeed the Government of Canada considers issues surrounding mental health as very important, not only to individual Canadians but to their families and their communities.

Health Canada works across this country to promote mental health, working at the grassroots level developing tools, programs and resources. We also support the CIHR which has funded recently to the tune of close to some $10 million 55 projects in communities of all sizes to learn more about the causes of mental illness and how we, our families and communities can deal with the challenges of mental illness.

Health Care May 28th, 2002

Mr. Speaker, here is another example of the hon. member's tactics in relation to scaremongering.

As I have said throughout, my provincial and territorial colleagues and I will make decisions on the basis of the best evidence.

The hon. member is suggesting that this is a useful study in terms of helping us understand those delivery modes which make the most sense in various circumstances. Absolutely. I think the McMaster study will be very useful to all of us in making those decisions.

Health Care May 28th, 2002

Mr. Speaker, as I have indicated before, if one presumes that provincial and territorial health ministers make decisions in relation to delivery methods for health care on the basis of evidence, the McMaster study is an important study. It is one study and I have no doubt that provincial and territorial colleagues will study it, just as I will.

Health May 28th, 2002

Mr. Speaker, what I will say is that which I said earlier, which is what is important is evidence on which provincial and territorial health care ministers can make decisions around how health care is delivered in this country. In relation to that, the Canadian Medical Association Journal article is in fact an important contribution. It is one which I am sure my provincial and territorial colleagues as well as myself will review very carefully and with great interest.

Health May 28th, 2002

Mr. Speaker, the hon. member misunderstands what I said. I do not advocate for profit hospitals. What I do advocate for is evidence based decision making.

The importance of the Canadian Medical Association Journal article is that it provides us with more evidence that provincial and territorial health care ministers can use in making decisions as to how to best deliver health care on behalf of all Canadians.

Health May 27th, 2002

Mr. Speaker, as the hon. members knows, if she put aside the rhetorical flourishes, we are very much involved with the renewal of health care, along with our provincial and territorial colleagues, other stakeholders and those who use our health care system. In fact the Romanow commission is concluding its national consultations with Canadians everywhere.

Senator Kirby and his senate committee are consulting with Canadians and others in relation to the future of health care.

In fact in September of 2000, the Prime Minister and the first ministers entered into an accord with $21.1 billion new dollars for health care.

Health May 27th, 2002

Mr. Speaker, the five principles of the Canada Health Act are fundamental to our health care system and the renewal of our health care system. My officials are monitoring and working with the officials in B.C. to ensure that the restructuring which takes place in the province of British Columbia does not violate the five principles of the Canada Health Act.

Let me remind the hon. member that all of us, federal, provincial and territorial ministers of health and governments, are working hard on behalf of our residents and citizens to renew our health care system and to have a health care system that is there for everyone when they need it.